Authors: Yile Huang Cong Zhang Cairen Chen Shilong Sun He Zheng Shuli Wan Qingyong Meng Yubin Chen Jun Wei
Publish Date: 2014/10/25
Volume: 36, Issue: 2, Pages: 1233-1236
Abstract
Our recent work demonstrated that circulating levels of IgG antibody to linear peptide antigens derived from annexin A1 ANXA1 were significantly increased in lung cancer The present study was then undertaken to test whether circulating antiANXA1 antibodies were also altered in breast cancer An enzymelinked immunosorbent assay was developed inhouse to determine circulating IgG against ANXA1derived peptide antigens in 152 female patients with breast cancer and 160 female control subjects Student’s t test revealed that patients with breast cancer had significantly higher levels of antiANXA1 IgG than control subjects t = 475 P 00001 Receiver operating characteristic ROC analysis showed that the area under the ROC curve was 073 with 95 confidence interval CI 067–078 and the sensitivity of antiANXA1 IgG assay was 232 against the specificity of 90 The levels of antiANXA1 IgG did not appear to be stagedependent and Pearson correlation analysis showed no correlation between the antiANXA1 IgG levels and the stages of breast cancer r = −002 df = 149 P = 0796 This work suggests that circulating IgG for ANXA1derived peptide antigens may have both diagnostic and prognostic values for breast cancer although further screening is needed to identify more such peptide antigens derived from tumorassociated antigensWe thank all the patients and control subjects for their participation in this study We also thank the Third Affiliated Hospital of Harbin Medical University Harbin China for the recruitment of patients with breast cancer This work was supported by YingJi Biotechnology Exploitation Co Ltd Shenzhen China and by Glory Biomedical Co Ltd Taipei Taiwan
Keywords: